A Study to Test the Effectiveness and Safety of a New Medication in the Treatment of Schizophrenia

NCT00088634 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

180

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Lurasidone
DRUG: Placebo

Sponsor

Sumitomo Pharma America, Inc.